FRIDAY, Dec. 13, 2024 -- An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast...

THURSDAY, Dec. 12, 2024 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast...

INDIANAPOLIS, Dec. 11, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant,...

INDIANAPOLIS, Dec. 11, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant,...

MONDAY, Dec. 16, 2024 -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an...

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy...

Plus Therapeutics, Inc, a clinical─stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for...

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's disease, achieving...

FRIDAY, Dec. 13, 2024 -- It's a decision no woman wants to have to make, but new research shows that young breast cancer patients with high-risk genes...

A groundbreaking  phase one clinical trial exploring a novel cell-based immunotherapy for breast cancer  has been accepted for publication in JAMA...